There's a new slate of executives running Bridge Pharmaceuticals, which has been touting its facilities in China for preclinical contract research services. D. Thomas Oakley, a Covance vet, is the new CEO, Patrik Jeanmonod has been promoted to CFO and Dr. Ronald J. Ma is the new chief scientific officer. No word on the fate of their predecessors, the CEO abruptly left the scene months ago, or what triggered the change up. Release